Table 1.

Epidemiological features and underlying conditions plus the results of the multivariable logistic regression in cases who survived or died following cerebral mucormycosis

Characteristics	Total n (%) N=345	Survived n (%) N=209	Dead n (%) N=136	OR (95% Cl)	P-value
Underlying conditions
South America	3 (0.9)	2 (1.5)	1 (0.5)
Alcohol use	10 (2.9)	4 (1.9)	6 (4.4)	1.02 (0.2 -3.7)	0.970
Burn	1 (0.3)	0 (0.0)	1 (0.7)	1.65 (1.5-1.8)	0.419
Chronic heart disease	11 (3.1)	3 (2.2)	8 (3.8)	0.5 (0.1-2.1)	0.537
Chronic kidney disease	32 (9.2)	5 (3.7)	27 (12.9)	0.257 (0.09-.686)	0.004
Chronic liver failure	18 (5.2)	3 (2.2)	15 (7.2)	0.2 (0.08-0.1)	0.04
Chronic lung disease	15 (4.3)	4 (2.9)	11 (5.3)	0.5 (0.1-1.7)	0.420
Concomitant infection	9 (2.6)	2 (1.5)	7 (3.3)	0.43 (0.08-20.1)	0.492
Corticosteroid use	37 (10.7)	22 (16.2)	15 (7.2)	2.4 (1.2-5)	0.008
Diabetes mellitus with ketoacidosis	14 (23.8)	6 (4.4)	8 (3.8)	1.16 (.393-3.419)	0.78
Diabetes mellitus without ketoacidosis	176 (51)	83 (61)	93 (44.5)	1.9 (1.2-3.0)	0.003
Hematological malignancy or Hematopoietic stem cell transplantation (HSCT)	80 (23.2)	25 (18.4)	55 (26.3)	0.6 (0.3-1.07)	0.088
Solid organ transplantation (SOT)	16 (4.6)	7 (5.1)	9 (4.3)	1.2 (0.4-3.3)	0.717
Hypertension	34 (9.8)	13 (9.6)	21 (10.0)	0.9 (0.4-1.9)	0.88
Graft versus host disease (GVHD)	11 (3.1)	3 (2.2)	8 (3.8)	0.5 (0.1-2.1)	0.537
Injection drug use	18 (5.2)	7 (5.1)	11 (5.3)	0.9 (0.3-2.5)	0.962
Other underlying conditions	29 (8.4)	7 (5.1)	22 (10.5)	1.6 (1.5-1.8)	0.07
Solid Tumor	6 (1.7)	2 (1.5)	4 (1.9)	0.7 (0.1-4.2)	0.758
Trauma	4 (1.2)	3 (2.2)	1 (0.5)	4.6 (0.4-45.5)	0.304
Vasculitis	12 (3.4)	2 (1.5)	10 (4.8)	0.297 (0.6-1.37)	0.135
Geographical distribution
Africa	4 (1.2)	1 (0.7)	3 (1.4)	-	0.694
Asia	87 (25.2)	30 (22.1)	57 (27.3)
European Union	84 (24.3)	35 (25.7)	49 (23.4)
Middle East	32 (9.3)	16 (11.8)	16 (7.7)
North America	130 (37.7)	50 (36.8)	80 (38.3)
Oceania	5 (1.4)	2 (1.5)	3 (1.4)